FOXD1 expression is associated with poor prognosis in non-small cell lung cancer

Sohei Nakayama, Kenzo Soejima, Hiroyuki Yasuda, Satoshi Yoda, Ryosuke Satomi, Shinnosuke Ikemura, Hideki Terai, Takashi Sato, Norihiro Yamaguchi, Junko Hamamoto, Daisuke Arai, Kota Ishioka, Keiko Ohgino, Katsuhiko Naoki, Tomoko Betsuyaku

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Aim: Clinical microarray datasets were analyzed to search for new therapeutic targets and prognostic markers of non-small cell lung cancer (NSCLC).

Materials and Methods: Microarray datasets from 90 lung cancer specimens, were analyzed with focus on the FOXD1 gene. Levels of FOXD1 mRNA were assessed in lung cancer cell lines and these levels were correlated with survival.

Results: FOXD1-knockdown led to suppression of cell proliferation. Moreover, patients with high FOXD1 expression survived for a significantly shorter time than those with low FOXD1 expression.

Conclusion: The expression status of FOXD1 is a novel prognostic factor and may lead to new treatment strategies for NSCLC.

Original languageEnglish
Pages (from-to)261-268
Number of pages8
JournalAnticancer research
Volume35
Issue number1
Publication statusPublished - 2015 Jan 1

    Fingerprint

Keywords

  • FOXD1
  • Microarray
  • Non-small cell lung cancer
  • PTEN
  • Pathway signature

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Nakayama, S., Soejima, K., Yasuda, H., Yoda, S., Satomi, R., Ikemura, S., Terai, H., Sato, T., Yamaguchi, N., Hamamoto, J., Arai, D., Ishioka, K., Ohgino, K., Naoki, K., & Betsuyaku, T. (2015). FOXD1 expression is associated with poor prognosis in non-small cell lung cancer. Anticancer research, 35(1), 261-268.